Gleevec or Glivec - Imatinib - Chronic Myeloid Leukemia



''Imatinib was developed in the late 1990s by biochemist Nicholas Lydon, a former researcher for Novartis, and oncologist Brian Druker of Oregon Health and Science University (OHSU). Other major contributions to imatinib development were made by Carlo Gambacorti-Passerini, a physician scientist at University of Milano Bicocca, Italy, John Goldman at Royal Hammersmith Hospital in London, UK, and later on by Charles Sawyers of Memorial Sloan-Kettering Cancer Center who led the clinical trials confirming its efficacy in CML''               
Extract from Wikipedia

"Jürg Zimmermann, a medicinal chemist, is the chemical inventor of the compound STI571 also called Gleevec''  
Extract from  Novartis

SITES

Picture extract from Wikipedia
Gleevec by Novartis
Glivec research Today
Gleevec by drugwatch

FORUMS 

Gleevec_CML
Gleevec              (Warning - old messages from 2001 to 2006)
Brain_Gleevec (Warning - old messages from 2001 to 2006
                                                                                                                                                                                                                                                                                                                         
Plasma exposure of imatinib and its correlation with clinical response  in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial
February 7, 2012, Haematologica
The Apothecary Shops Incorporates Innovative Technology Into Patient Medication Reminders
December 19, 2011, PRNewswire

Imatinib is receptive to a collaboration
October 13, 2011, Journal Blood

Leukemia Patients Taking Gleevec Achieve ‘Normal’ Death Rate
March 22, 2011, HealthDay News

Seven-year follow-up of patients receiving imatinib for the treatment of newly diagnosed chronic myelogenous leukemia by the TARGET system.
December 15, 2010, CMLHope.com

Principal long-term adverse effects of imatinib in patients with chronic myeloid leukemia in chronic phase
December 2, 2010, Dovepress

Important correction of drug information about Gleevec
September 2010,   Novartis

Combination of simvastatin and imatinib sensitizes the CD34+ cells in K562 to cell death
March 31, 2010, Mendeley

Researcher Behind the Drug Gleevec
November 2009, The New York Times

GIST Q&A with Dr. Peter Reichardt
2007 by  Life Raft Group